Synthetic Polymeric Antibacterial Hydrogel for Methicillin-Resistant Staphylococcus aureus-Infected Wound Healing: Nanoantimicrobial Self-Assembly, Drug- and Cytokine-Free Strategy

Sea Cucumber (Stichopus sp) belongs to Holothuroidea family. Sea Cucumber has lot of uses in the medicine sector, such as: for wound healing, anti-biotic, anti-bacteria, anti-tumor, and anti-coagulation. Diabetes mellitus is a disease characterized by high blood sugar levels with metabolic disorders. This disease can cause wounds called gangrene This research has purpose to prove the influence of giving nano spray of sea cucumber extract within 14 days. In the in vitro examination found 40% concentration of sea cucumber extract which is effective to resist the growth of Methicillin Resistant Staphylococcus aureus bacteria and examined to wistar mouse which are already diabetic inducted with Streptozotocin (STZ) and hurt with punch biopsy with the diameter of 0,8 cm on its back and the wound is infected with bacteria which is intradermal injected. Divided into 3 groups : (K-) no medical treatment, nano spray of sea cucumber extract (T), Nano spray penicillin (K+) to wistar mouse towards the speed of diabetic mellitus wound healing which is infected by Methicillin Resistant Staphylococcus aureus bacteria. Parameter used to measure the rate of wound healing is wound size and hitopathology examination.After it’s regularly given the medicine, the result of nano spray sea cucumber extract 40 % concetration category treatment on wound healing process the diameter of wound on the 3rd day 0.8 cm , on the 7th day 0.4 cm and on the 14th day wound fully recover according to macros (wound size) and histopathology examination shows faster and better healing compared to treatment category of nano spray penicillin and control marked by score cell and lymphocyte in a small quantity.

Download Full-text

Abstract 10200: Translational Research of Novel Angiogenic Peptide for Wound Healing Drug; From Discovery to Clinical Trial

Circulation ◽

10.1161/circ.132.suppl_3.10200 ◽

2015 ◽

Vol 132 (suppl_3) ◽

Author(s):

Hironori Nakagami ◽

Ryuichi Morishita

Keyword(s):

Clinical Trial ◽

Staphylococcus Aureus ◽

Wound Healing ◽

Drug Development ◽

Methicillin Resistant Staphylococcus Aureus ◽

Skin Ulcer ◽

Secondary Outcome ◽

Double Blind Study ◽

Full Thickness ◽

Methicillin Resistant

We developed a novel cationic peptide, AG30/5C, with angiogenic properties. Since it has both angiogenic and antimicrobial actions, it might be a candidate peptide for wound healing drug. We conducted a physician-initiated clinical trial of AG30/5C for severe skin ulcer in patients as an open label study. The primary outcome is safety because it is first in human trial on early stage. AG30/5C was administered with patients with skin ulcer twice per day for two weeks, and ulcer size and Methicillin-Resistant Staphylococcus Aureus amount was quantified as a secondary outcome. Two patients was registered until now and the skin ulcer of first patient was completely cured after AG30/5C treatment. The Methicillin-Resistant Staphylococcus Aureus amount of both patients was decreased during the AG30/5C treatment. This result suggests the potential of AG30/5C as a wound healing drug, however, improvement of stability and cost efficiency are required toward drug development. Thus, we addressed to the metabolites of AG30/5C which can provide a further optimized compound, SR-0379. SR-0379 also enhanced proliferation, tube formation, migration and contraction on human dermal fibroblast cells via the PI3K-Akt-mTOR pathway through integrin-mediated interactions. We evaluated the effect of SR-0379 on two different would healing model in rats, the full-thickness defects in diabetic condition and an acutely infected wound with the full-thickness defects and inoculation with S aureus. Treatment of SR-0379 significantly accelerated the wound healing compared to that of FGF2. The beneficial effects of SR-0379 on wound healing would be explained by enhanced angiogenesis, granulation tissue formation, proliferation and antimicrobial activity. These results clearly demonstrated that SR-0379 may have a potential for drug development in wound repairing, in especially critical colonization condition. Based on these results, we now conducted the physician-initiated clinical trial for severe skin ulcer in patients as a double blind study.

Download Full-text